Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1373 - Genomic profiling for advanced non-small-cell lung cancer (NSCLC) from circulating tumour DNA (ctDNA) (551P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Herbert Loong

Citation

Annals of Oncology (2017) 28 (suppl_10): x173-x176. 10.1093/annonc/mdx679

Authors

H. Loong1, V. Raymond2, D.T..T. Chua3, P.M..L. Teo4, T. Yung5, R.B. Lanman6, S. Skrzypczak6, T.S.K. Mok1

Author affiliations

  • 1 Department Of Clinical Oncology, The Chinese University of Hong Kong, 00000 - Hong Kong/HK
  • 2 Medical Affairs, Guardant Health, 94063 - Redwood City/US
  • 3 Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong/HK
  • 4 -, Central Comprehensive Cancer Centre, Hong Kong/HK
  • 5 -, Sanomics Limited, Hong Kong/HK
  • 6 -, Guardant Health, 94063 - Redwood City/US
More

Resources

Abstract 1373

Background

Genomic profiling of ctDNA has proven to be an effective alternative to repeat invasive biopsy in patients (pts) with advanced cancers. There is also the advantage of a more comprehensive approach over tissue-based assays with the ability to provide a summary of tumour heterogeneity.

Methods

We performed a retrospective review of Hong Kong pts with advanced/metastatic NSCLC whose physician requested ctDNA-based genomic profiling utilizing the Guardant360 platform between Jan 2016 - Jun 2017. Guardant360 includes all four major types of genomic alterations (point mutations, and selected indels, fusions, and amplifications) and completely sequences exons in 73 target genes.

Results

ctDNA testing was performed in 76 pts over this 18-month period (Median Age: 59.5 years (range 42-87), M:F 41:35). Histologies, as reported by the ordering physician, include squamous (SqCC) (n = 7), adenocarcinoma (Adeno) (n = 10), and NSCLC-not otherwise specified (NSCLC-NOS) (n = 58). In SqCC, all 7 pts had multiple detectable variants identified (range: 2-20 variants, median = 6), including FGFR1 amplification (n = 3), ERBB2 (HER2) amplification (n = 2). PIK3CA amplification occurred in combination with either FGFR1 or ERBB2 (HER2) amplification (n = 1 each), or alone (n = 1). In the Adeno and NSCLC-NOS groups combined, 91% of pts (61/68) had variants identified (range: 1-12 variants, median = 3), of which 42% (26/62) had at least one of the seven NCCN recommended lung adenocarcinoma genomic targets (EGFR (21%), EML4-ALK (8.1%), ERBB2 exon 20 insertion (6%), MET Amp (3.2%), ROS1 (2%), BRAF V600E (2%)). Concurrent detection of driver and resistance mutations were identified in 6/13 patients with EGFR driver mutations (T790M (n = 1), T790M/C797S (n = 1), MET amp (n = 2), T790M/MET amp (n = 1) and ERBB2 amp (n = 1)) and in 3/5 patients with EML4-ALK fusion (MET exon 14 skipping (n = 1) and the ALK L1196M gatekeeper mutation (n = 2)).

Conclusions

Genomic profiling utilizing ctDNA analysis detected alterations in majority of advanced NSCLC pts, with targetable aberrations and resistance mechanisms identified. This approach has prompted changes in matched therapy in selected pts, and has demonstrated its feasibility in Asia.

Clinical trial identification

Legal entity responsible for the study

The Chinese University of Hong Kong

Funding

None

Disclosure

H. Loong: Advisory Board: Celgene, Novartis, Roche Travel Support: BMS, MSD, Novartis, Roche, TaiHo Speakers\' Bureau: Abbvie, Novartis Research Funding: MSD, Mundipharma, V. Raymond: Employee of Guardant Health. T. Yung: Employee of Sanomics Limited. R.B. Lanman: Employee and shareholder of Guardant Health. S. Skrzypczak: Employee of Guardant Health, T.S.K. Mok: Shareholder of Sanomics Limited.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.